Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Psychosis: Pathophysiology of Schizophrenia and Other Psychotic Disorders01:27

Psychosis: Pathophysiology of Schizophrenia and Other Psychotic Disorders

852
Schizophrenia is a neurodevelopmental disorder whose origins are rooted in complex genetic components. Despite our burgeoning understanding, the pathophysiology of this disorder remains incompletely deciphered.
Researchers have identified genetic factors that increase susceptibility to schizophrenia, underscoring the intricate interplay between genetics and environment in disease development. At the core of schizophrenia's pathophysiology is excessive dopaminergic neurotransmission within...
852
Antiepileptic Drugs: Glutamate Antagonists01:14

Antiepileptic Drugs: Glutamate Antagonists

473
Glutamate is a fundamental neurotransmitter in the central nervous system, playing a vital role in neuronal communication and various cognitive processes. Glutamate stands as the principal excitatory neurotransmitter in the brain. Its presence is crucial for the communication between neurons, underpinning essential processes such as synaptic transmission, neuronal excitability, and plasticity. These functions are vital for higher-order cognitive processes, including learning and memory. The...
473
Positive Symptoms of Schizophrenia: Hallucinations and Delusions01:30

Positive Symptoms of Schizophrenia: Hallucinations and Delusions

201
Schizophrenia is a complex mental health disorder that can manifest with various positive symptoms, including thought, movement, and behavior disorders. These symptoms significantly disrupt cognitive and motor functions, leading to profound effects on an individual's ability to engage with the world.
Thought Disorders
Disorganized and unusual thought processes mark thought disorders in schizophrenia. One key feature is disorganized speech, where an individual's conversation includes...
201
Drugs Acting on Autonomic Ganglia: Stimulants01:23

Drugs Acting on Autonomic Ganglia: Stimulants

1.4K

Ganglionic stimulants activate NM nicotinic receptors in autonomic ganglia, falling into two categories: nicotine mimetics [e.g., lobeline, dimethylpiperazine, tetramethylammonium] and muscarinic receptor agonists [e.g., muscarine, methacholine]. The first category's action is rapid and blocked by nicotinic receptor antagonists, while the second category's action is delayed and blocked by atropine-like agents. Nicotine, an alkaloid, affects the heart rate by stimulating...
1.4K
Biological Causes of Schizophrenia01:29

Biological Causes of Schizophrenia

115
Schizophrenia, a severe psychiatric disorder, arises from a complex interplay of biological factors, including genetic predisposition, structural brain abnormalities, neurotransmitter dysregulation, and developmental irregularities. These factors collectively contribute to the onset and progression of the disorder, which typically manifests in late adolescence or early adulthood.
Genetic Factors in Schizophrenia
The genetic basis of schizophrenia is strongly supported by family and twin...
115
Psychosis: Goals of Pharmacotherapy01:26

Psychosis: Goals of Pharmacotherapy

185
Antipsychotic drugs are a crucial treatment method for acute and chronic psychoses, bipolar illness, and behavioral disorders. The selection of these drugs depends on several factors, including the state of the disease, clinical judgment, possible drug interactions, and the patient's sensitivity to adverse effects. In immediate scenarios, such as delirium and dementia, short-term treatment with low doses of high-potency typical or atypical agents can effectively manage symptom exacerbation.
185

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

NeuroMark-SZ: A Holistic Resting-State-fMRI-Based Model for Divergent Functional Circuitry in Schizophrenia.

bioRxiv : the preprint server for biology·2026
Same author

Mapping the Psychosis Spectrum - Imaging Neurosubtypes from Multi-Scale Functional Network Connectivity.

bioRxiv : the preprint server for biology·2025
Same author

Static and Dynamic Cross-Network Functional Connectivity Shows Elevated Entropy in Schizophrenia Patients.

Human brain mapping·2025
Same author

Associations of alcohol and tobacco use with psychotic, depressive and developmental disorders revealed via multimodal neuroimaging.

Translational psychiatry·2024
Same author

Static and Dynamic Cross-Network Functional Connectivity Shows Elevated Entropy in Schizophrenia Patients.

bioRxiv : the preprint server for biology·2024
Same author

Cortical morphology in patients with the deficit and non-deficit syndrome of schizophrenia: a worldwide meta- and mega-analyses.

Molecular psychiatry·2023
Same journal

Latent subdimensions of anxiety and depression differentially influence exertion of effort in pursuit of reward versus avoidance of threat.

Translational psychiatry·2026
Same journal

The cell-type specific interaction based drug repurposing for psychiatric disorders.

Translational psychiatry·2026
Same journal

Psychotropic drug-induced weight gain and untargeted metabolomics: machine learning-driven results from a prospective cohort study.

Translational psychiatry·2026
Same journal

The effects of propranolol and corticosterone on susceptibility priming in a mouse model of social defeat stress.

Translational psychiatry·2026
Same journal

The physiological foundation of extinction improvement by tDCS over the ventromedial prefrontal cortex (vmPFC) in healthy humans: an fMRI study.

Translational psychiatry·2026
Same journal

Multi-ancestry multi-trait analysis reveals shared genetics across major psychiatric disorders and Alzheimer's disease.

Translational psychiatry·2026
See all related articles

Related Experiment Video

Updated: Aug 19, 2025

Standardized Data Acquisition for Neuromelanin-Sensitive Magnetic Resonance Imaging of the Substantia Nigra
05:14

Standardized Data Acquisition for Neuromelanin-Sensitive Magnetic Resonance Imaging of the Substantia Nigra

Published on: September 8, 2021

3.6K

Glutamatergic dysfunction in Schizophrenia.

Andreas O Kruse1, Juan R Bustillo2

  • 1Department of Psychiatry and Behavioral Sciences, University of New Mexico, Albuquerque, NM, 87131, USA. aokruse@salud.unm.edu.

Translational Psychiatry
|December 3, 2022
PubMed
Summary
This summary is machine-generated.

The NMDA-R hypofunction model of schizophrenia is supported by clinical and preclinical evidence, but its specific role remains unclear. Future research requires advanced tools to investigate glutamatergic, GABA-ergic, and dopaminergic systems.

More Related Videos

HSV-Mediated Transgene Expression of Chimeric Constructs to Study Behavioral Function of GPCR Heteromers in Mice
07:30

HSV-Mediated Transgene Expression of Chimeric Constructs to Study Behavioral Function of GPCR Heteromers in Mice

Published on: July 9, 2016

7.4K
Single Synapse Indicators of Glutamate Release and Uptake in Acute Brain Slices from Normal and Huntington Mice
08:27

Single Synapse Indicators of Glutamate Release and Uptake in Acute Brain Slices from Normal and Huntington Mice

Published on: March 11, 2020

6.3K

Related Experiment Videos

Last Updated: Aug 19, 2025

Standardized Data Acquisition for Neuromelanin-Sensitive Magnetic Resonance Imaging of the Substantia Nigra
05:14

Standardized Data Acquisition for Neuromelanin-Sensitive Magnetic Resonance Imaging of the Substantia Nigra

Published on: September 8, 2021

3.6K
HSV-Mediated Transgene Expression of Chimeric Constructs to Study Behavioral Function of GPCR Heteromers in Mice
07:30

HSV-Mediated Transgene Expression of Chimeric Constructs to Study Behavioral Function of GPCR Heteromers in Mice

Published on: July 9, 2016

7.4K
Single Synapse Indicators of Glutamate Release and Uptake in Acute Brain Slices from Normal and Huntington Mice
08:27

Single Synapse Indicators of Glutamate Release and Uptake in Acute Brain Slices from Normal and Huntington Mice

Published on: March 11, 2020

6.3K

Area of Science:

  • Neuroscience
  • Psychiatry
  • Pharmacology

Background:

  • The NMDA-R hypofunction model of schizophrenia is based on observations of psychosis induced by NMDA-R antagonists like ketamine and PCP.
  • Ketamine and PCP induce psychosis, negative, and cognitive symptoms in humans and alter neurotransmitter levels in rodents and humans.
  • Schizophrenia is associated with reduced dendritic complexity and NMDA-R subunit reductions in post-mortem studies.

Purpose of the Study:

  • To review the evidence supporting the NMDA-R hypofunction model of schizophrenia.
  • To evaluate the therapeutic implications of this model for schizophrenia treatment.
  • To suggest future research directions for understanding glutamatergic dysfunction in schizophrenia.

Main Methods:

  • Review of clinical observations, preclinical studies (rodent models), post-mortem human studies, and genetic and pharmacological literature.
  • Analysis of in-vivo studies using proton magnetic resonance spectroscopy (¹H-MRS) and positron emission tomography (PET).
  • Examination of pharmacological interventions targeting the NMDA-R pathway.

Main Results:

  • NMDA-R antagonist administration mimics schizophrenia symptoms and alters glutamate and dopamine levels.
  • Studies show reduced dendritic complexity and NMDA-R subunit deficits in schizophrenia.
  • Genetic studies indicate a role for glutamate-related genes, and pharmacological trials have shown limited success.
  • Glutamate levels are altered in schizophrenia, particularly early in the illness.

Conclusions:

  • While glutamatergic abnormalities are present in schizophrenia, the specific role of NMDA-R hypofunction is not definitively established.
  • Current pharmacological approaches targeting NMDA-R have not yielded significant clinical benefits.
  • A comprehensive understanding of interacting neurotransmitter systems is crucial for developing next-generation schizophrenia treatments.